Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 1
1979 2
1982 3
1983 1
1984 3
1985 1
1986 2
1987 3
1988 1
1989 3
1990 1
1991 5
1992 3
1993 3
1994 8
1995 11
1996 6
1997 9
1998 8
1999 8
2000 5
2001 7
2002 6
2003 7
2004 8
2005 5
2006 5
2007 11
2008 5
2009 11
2010 11
2011 11
2012 12
2013 23
2014 10
2015 21
2016 19
2017 12
2018 17
2019 17
2020 21
2021 18
2022 17
2023 13
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

341 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Pituitary adenoma, growth hormone-secreting, 2"
Page 1
Diagnosis and Treatment of Acromegaly: An Update.
Ershadinia N, Tritos NA. Ershadinia N, et al. Mayo Clin Proc. 2022 Feb;97(2):333-346. doi: 10.1016/j.mayocp.2021.11.007. Mayo Clin Proc. 2022. PMID: 35120696 Review.
Acromegaly is typically caused by a growth hormone-secreting pituitary adenoma, driving excess secretion of insulin-like growth factor 1. ...Early diagnosis and adequate treatment are essential to mitigate excess mortality associated with …
Acromegaly is typically caused by a growth hormone-secreting pituitary adenoma, driving excess secretion …
Diagnosis and Treatment of Pituitary Adenomas: A Review.
Molitch ME. Molitch ME. JAMA. 2017 Feb 7;317(5):516-524. doi: 10.1001/jama.2016.19699. JAMA. 2017. PMID: 28170483 Review.
Prolactinomas account for 32% to 66% of adenomas and present with amenorrhea, loss of libido, galactorrhea, and infertility in women and loss of libido, erectile dysfunction, and infertility in men; they are generally treated with the dopamine agonists cabergoline and bromocripti …
Prolactinomas account for 32% to 66% of adenomas and present with amenorrhea, loss of libido, galactorrhea, and infertility in women and los …
Modern approach to resistant acromegaly.
Giustina A, di Filippo L, Uygur MM, Frara S. Giustina A, et al. Endocrine. 2023 May;80(2):303-307. doi: 10.1007/s12020-023-03317-7. Epub 2023 Feb 15. Endocrine. 2023. PMID: 36790521
BACKGROUND: Targets of acromegaly treatment are normalization of biochemical values, removal/reduction/stabilization of the pituitary mass, control of clinical activity and mortality with a multimodal/multidisciplinary approach. Despite significant technological and pharma …
BACKGROUND: Targets of acromegaly treatment are normalization of biochemical values, removal/reduction/stabilization of the pituitary …
Clinical features and therapeutic outcomes of GH/TSH cosecreting pituitary adenomas: experience of a single pituitary center.
Yu N, Duan L, Hu F, Yang S, Liu J, Chen M, Yao Y, Deng K, Feng F, Lian X, Mao X, Zhu H. Yu N, et al. Front Endocrinol (Lausanne). 2023 May 30;14:1197244. doi: 10.3389/fendo.2023.1197244. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37324275 Free PMC article.
BACKGROUND: Growth hormone (GH)/thyroid stimulating hormone (TSH) cosecreting pituitary adenoma (PA) is an exceedingly rare kind of bihormonal pituitary neuroendocrine tumors (PitNETs). ...In addition, higher occurrence rates of arrhythmi …
BACKGROUND: Growth hormone (GH)/thyroid stimulating hormone (TSH) cosecreting pituitary adenoma (PA) is a …
Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly-A Prospective Study.
Ilie MD, Tabarin A, Vasiljevic A, Bonneville JF, Moreau-Grangé L, Schillo F, Delemer B, Barlier A, Figarella-Branger D, Bisot-Locard S, Santos A, Chanson P, Raverot G. Ilie MD, et al. J Clin Endocrinol Metab. 2022 Nov 23;107(11):2982-2991. doi: 10.1210/clinem/dgac512. J Clin Endocrinol Metab. 2022. PMID: 36136828
METHODS: We conducted a multicentric, prospective, observational cohort study, in France. Forty-nine naive patients (ie, patients without preoperative SRL treatment) with active acromegaly following surgery were treated with octreotide (group 1; n = 47), or pasireotide if …
METHODS: We conducted a multicentric, prospective, observational cohort study, in France. Forty-nine naive patients (ie, patients wit …
Epidemiology of acromegaly.
Holdaway IM, Rajasoorya C. Holdaway IM, et al. Pituitary. 1999 Jun;2(1):29-41. doi: 10.1023/a:1009965803750. Pituitary. 1999. PMID: 11081170 Review.
Acromegaly is a consequence of chronic growth hormone (GH) excess, due in the majority of cases to a GH-secreting pituitary adenoma, and occurring with a population prevalence of 60 per million and an incidence of 3-4 per million per year. ...Su …
Acromegaly is a consequence of chronic growth hormone (GH) excess, due in the majority of cases to a GH-secreting pi …
Delayed Remission of Growth Hormone-Secreting Pituitary Adenoma After Transsphenoidal Adenectomy.
Wang Z, Guo X, Gao L, Feng C, Lian W, Deng K, Bao X, Feng M, Wang R, Xing B. Wang Z, et al. World Neurosurg. 2019 Feb;122:e1137-e1145. doi: 10.1016/j.wneu.2018.11.004. Epub 2018 Nov 14. World Neurosurg. 2019. PMID: 30447463
OBJECTIVE: To investigate the clinical characteristics of delayed remission (DR) of growth hormone (GH)-secreting pituitary adenoma after transsphenoidal adenectomy and inform follow-up treatments. ...However, the best predictor of long-t …
OBJECTIVE: To investigate the clinical characteristics of delayed remission (DR) of growth hormone (GH)-secreting pi …
Radiomics model predicts granulation pattern in growth hormone-secreting pituitary adenomas.
Park YW, Kang Y, Ahn SS, Ku CR, Kim EH, Kim SH, Lee EJ, Kim SH, Lee SK. Park YW, et al. Pituitary. 2020 Dec;23(6):691-700. doi: 10.1007/s11102-020-01077-5. Pituitary. 2020. PMID: 32851505
PURPOSE: To investigate whether radiomic features from magnetic resonance image (MRI) can predict the granulation pattern of growth hormone (GH)-secreting pituitary adenoma patients. ...CONCLUSION: Radiomic features may be useful biomarke …
PURPOSE: To investigate whether radiomic features from magnetic resonance image (MRI) can predict the granulation pattern of growt …
Comparative analysis of pituitary adenoma with and without apoplexy in pediatric and adolescent patients: a clinical series of 80 patients.
Wang R, Wang Z, Song Y, Li L, Han X, Han S. Wang R, et al. Neurosurg Rev. 2022 Feb;45(1):491-498. doi: 10.1007/s10143-021-01551-z. Epub 2021 Apr 29. Neurosurg Rev. 2022. PMID: 33914243
The study included 33 boys and 47 girls, with a mean age of 16.9 years. There were six (7.5%) adrenocorticotropic hormone-secreting, 13 (16.3%) growth hormone-secreting, 47 (58.7%) prolactin-secreting, and 14 (17.5%) non-functioning PAs. …
The study included 33 boys and 47 girls, with a mean age of 16.9 years. There were six (7.5%) adrenocorticotropic hormone-secretin …
ENDOCRINE TUMOURS: Thyrotropin-secreting pituitary adenoma: a structured review of 535 adult cases.
De Herdt C, Philipse E, De Block C. De Herdt C, et al. Eur J Endocrinol. 2021 Jul 12;185(2):R65-R74. doi: 10.1530/EJE-21-0162. Eur J Endocrinol. 2021. PMID: 34132199
BACKGROUND AND AIMS: Thyrotropin-secreting pituitary adenomas (TSHomas) are a rare entity, occurring in one per million people. ...The majority (76.9%) of the TSHomas were macroadenoma. Plurihormonality was seen in 37.4% of the adenoma with a higher incidence …
BACKGROUND AND AIMS: Thyrotropin-secreting pituitary adenomas (TSHomas) are a rare entity, occurring in one per million people …
341 results